Myriad Genetics (MYGN) Non-Current Assets (2010 - 2026)

Myriad Genetics (MYGN) has 17 years of Non-Current Assets data on file, last reported at $360.9 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $360.9 million, down 49.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (down 50.13% YoY), and the FY2025 annual result was $374.0 million, down 48.74% from the prior year.
• Non-Current Assets retreated to $360.9 million in Q1 2026 per MYGN's latest filing, from $374.0 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $924.1 million in Q4 2022 and troughed at $360.9 million in Q1 2026.
• A 5-year average of $725.5 million and a median of $820.2 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2025: Non-Current Assets rose 10.55% in 2022, then sank 51.36% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $924.1 million in 2022, then retreated by 9.87% to $832.9 million in 2023, then fell by 12.4% to $729.6 million in 2024, then tumbled by 48.74% to $374.0 million in 2025, then decreased by 3.5% to $360.9 million in 2026.
• Business Quant data shows MYGN's Non-Current Assets at $360.9 million in Q1 2026, $374.0 million in Q4 2025, and $383.3 million in Q3 2025.